Cannabinoid Synthesis and Purification Development Processes

With the discovery of the CB-2 receptor, the scientific community has seen a renewed interest in the therapeutic potential of cannabinoids for a variety of illnesses,including autoimmune diseases. There are now a growing number of studies that indicate the CB₂ receptor is closely linked to a variety of functional responses of the immune system and that cannabinoids can suppress the antibody response of humans and animals. In fact, there are at least three cannabinoid based pharmaceuticals on the market today, Marinol, Nabilone and Sativex.

Scientists are researching the ability of cannabinoid receptors to modulate several physiological systems, including the immune system. It is thought that cannabinoids and synthetic analogues of cannabinoids (exogenous cannabinoids) can alter the activities of immune cells as well as activate cannabinoid receptors, inhibiting a wide variety of immune cells and decreasing the production of cytokines.

Exogenous cannabinoids, such as delta-9-tetrahydrocannabinol (THC), have also been reported to have the ability to inhibit cell recruitment and modulate the migration of immune cells to the site of an infection or injury.

Additionally, the ability to selectively administer and suppress Th1-promoting cytokines also increases the possibility of using cannabinoids in new treatments for autoimmune diseases.

New Delta-9-tetrahydrocannabinol Process

Cedaburg Hauser chemists have developed a process that produces delta-9-THC, one of the most challenging members of the cannabinoid family, and the active ingredient in Marinol.

The process used to produce multi-kilogram quantities of the key intermediate used to production of THC analogs, has been published by Cedarburg Hauser scientists.

Large-Scale Preparation of (+)-p-Menth-2-ene-1,8-diol, a Key Intermediate in the Synthesis of delta-9-Tetrahydrocannabinol.

Abstract:
A manufacturing-scale process for the preparation of p-menth-2-ene-1,8-diol, a key intermediate for the preparation of Δ-9-tetrahydrocannabinol (Δ-9-THC), was developed. The process entails a large-scale olefin migration/epoxidation and hydrolytic epoxide opening in organic solvent. The water-soluble product is isolated without the need for exhaustive extraction.

Detailed Listing:
“Large-Scale Preparation of (+)-p-Menth-2-ene-1,8-diol, a Key Intermediate in the Synthesis of delta-9-Tetrahydrocannabinol.” Cabaj, J. E.; Lukesh, J. M.; Pariza, R. P.; Zizelman, P. M. Org. Process Res. Dev. 2009, 13, 358).

Cannabinoid Synthesis and Purification Expertise

Our experience and expertise in developing cannabinoid synthesis and purification processes can help you both design and develop scalable chemistry for your drug or drug candidate. Our experience in process validation, scale up and manufacturing allows us to carry our process into kilogram and ultimately commercial scale production. We can use our experience and expertise with cannabinoid synthesis and purification to help your autoimmune therapeutic drug development project become a success.

Tell us about your project

If you need a company that has experience and proven success of designing and developing cannabinoid synthesis and purification processes, you can feel confident in trusting Cedarburg Hauser Pharmaceuticals to get the job done. We would love to learn more about your project and explore how we can use our experience and expertise in cannabinoid synthesis and purification, as well as delta-9-tetrahydrocannabinol, to help you achieve the successful outcome you are looking for.